Censavudine

Source: Wikipedia, the free encyclopedia.
Censavudine
Clinical data
Other names4'-ethynylstavudine, festinavir
Legal status
Legal status
  • Investigational
Identifiers
  • 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
JSmol)
  • CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
  • InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1
  • Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N

Censavudine (INN)

Bristol Myers-Squibb for the treatment of HIV infection.[2][3] It was originally developed at Yale University.[4] It is still in an investigational phase of development as of 2023.[5]

Renaming

Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).[6]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 110" (PDF). World Health Organization. pp. 409–410.
  2. PMID 28559249
    .
  3. .
  4. ^ Alcorn K (21 December 2010). "Bristol-Myers Squibb buys festinavir, new NRTI active against MDR HIV". aidsmap.com. aidsmap. Retrieved 24 June 2011.
  5. ^ PubChem. "Censavudine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-24.
  6. ^ PubChem. "Censavudine". pubchem.ncbi.nlm.nih.gov. Retrieved 2023-10-24.